{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:34:28Z","timestamp":1791581668026,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T00:00:00Z","timestamp":1521072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Olanzapine is an effective antipsychotic drug but since it causes significant weight gain, it is not well tolerated by psychosis patients. The prebiotic, B-GOS<jats:sup>\u00ae<\/jats:sup>, attenuates metabolic dysfunction in obese subjects, and in rodents, alters central NMDA receptors and may affect serotonin receptors that are relevant in psychosis. We have determined whether B-GOS<jats:sup>\u00ae<\/jats:sup>influenced olanzapine-associated weight gain and central NMDA and serotonin receptors. Circulating acetate, IL-1\u03b2, IL-8 and TNF\u03b1, liver acetyl-CoA carboxylase (ACC), white adipose tissue (WAT) acetate receptor GPR43, and specific faecal bacteria genera were also measured to provide mechanistic information. Adult female Sprague-Dawley rats were administered a B-GOS<jats:sup>\u00ae<\/jats:sup>(0.5\u2009g\/kg\/day) solution or water for 21 days, and received a single, daily, intraperitoneal injection of olanzapine or saline on days 8\u201321. The intake of B-GOS<jats:sup>\u00ae<\/jats:sup>significantly attenuated olanzapine-induced weight gain without altering frontal cortex 5-HT2AR blockade. Cortical GluN1 levels were elevated by olanzapine in the presence of B-GOS<jats:sup>\u00ae<\/jats:sup>. Plasma acetate concentrations increased following B-GOS<jats:sup>\u00ae<\/jats:sup>or olanzapine administration alone, but reduced when prebiotic and drug were administered in combination. This pattern was paralleled by hepatic ACC mRNA expression. The abundance of WAT GPR43 mRNA was reduced by olanzapine, only in the absence of B-GOS<jats:sup>\u00ae<\/jats:sup>. Co-administration of B-GOS<jats:sup>\u00ae<\/jats:sup>and olanzapine also elevated plasma TNF\u03b1, which is reported to influence lipid metabolism. Finally, B-GOS<jats:sup>\u00ae<\/jats:sup>elevated faecal<jats:italic>Bifidobacterium<\/jats:italic>spp. and reduced some bacteria in the Firmicutes phylum, whilst olanzapine treatment either alone or with B-GOS<jats:sup>\u00ae<\/jats:sup>, was without effect. These data suggest that inclusion of B-GOS<jats:sup>\u00ae<\/jats:sup>as an adjunct to olanzapine treatment in schizophrenia may prevent weight gain and have benefits on cognitive function in psychosis. The role of acetate in these effects requires further investigation.<\/jats:p>","DOI":"10.1038\/s41398-018-0116-8","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T11:22:08Z","timestamp":1521026528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Prebiotic attenuation of olanzapine-induced weight gain in rats: analysis of central and peripheral biomarkers and gut microbiota"],"prefix":"10.1038","volume":"8","author":[{"given":"Amy Chia-Ching","family":"Kao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-8786","authenticated-orcid":false,"given":"Belinda","family":"Lennox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip W. J.","family":"Burnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,15]]},"reference":[{"key":"116_CR1","doi-asserted-by":"crossref","unstructured":"Komossa K., et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 2010; CD006654.","DOI":"10.1002\/14651858.CD006654.pub2"},{"key":"116_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112","volume":"9","author":"M Bak","year":"2014","unstructured":"Bak, M., Fransen, A., Janssen, J., van Os, J. & Drukker, M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 9, e94112 (2014).","journal-title":"PLoS ONE"},{"key":"116_CR3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","volume":"156","author":"DB Allison","year":"1999","unstructured":"Allison, D. B. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 156, 1686\u20131696 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"116_CR4","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.orcp.2015.08.012","volume":"10","author":"D Arterburn","year":"2016","unstructured":"Arterburn, D. et al. Antipsychotic medications and extreme weight gain in two health systems. Obes. Res. & Clin. Pract. 10, 408\u2013423 (2016).","journal-title":"Obes. Res. & Clin. Pract."},{"key":"116_CR5","doi-asserted-by":"publisher","first-page":"893629","DOI":"10.1155\/2011\/893629","volume":"2011","author":"N Nihalani","year":"2011","unstructured":"Nihalani, N., Schwartz, T. L., Siddiqui, U. A. & Megna, J. L. Weight gain, obesity, and psychotropic prescribing. J. Obes. 2011, 893629 (2011).","journal-title":"J. Obes."},{"key":"116_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","volume":"41","author":"G Ratzoni","year":"2002","unstructured":"Ratzoni, G. et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J. Am. Acad. Child. Adolesc. Psychiatry 41, 337\u2013343 (2002).","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"116_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/schbul\/sbt090","volume":"39","author":"H Takeuchi","year":"2013","unstructured":"Takeuchi, H. et al. Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr. Bull. 39, 993\u2013998 (2013).","journal-title":"Schizophr. Bull."},{"key":"116_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.coph.2011.02.007","volume":"11","author":"HY Meltzer","year":"2011","unstructured":"Meltzer, H. Y. & Massey, B. W. The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr. Opin. Pharmacol. 11, 59\u201367 (2011).","journal-title":"Curr. Opin. Pharmacol."},{"key":"116_CR9","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.neuroscience.2009.09.041","volume":"164","author":"M Han","year":"2009","unstructured":"Han, M., Huang, X. F., du Bois, T. M. & Deng, C. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience 164, 1754\u20131763 (2009).","journal-title":"Neuroscience"},{"key":"116_CR10","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.pharep.2016.06.003","volume":"68","author":"J Lian","year":"2016","unstructured":"Lian, J., Pan, B. & Deng, C. Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacol. Rep. 68, 1028\u20131035 (2016).","journal-title":"Pharmacol. Rep."},{"key":"116_CR11","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.3390\/biom5043448","volume":"5","author":"KN Fedder","year":"2015","unstructured":"Fedder, K. N. & Sabo, S. L. On the role of glutamate in presynaptic development: possible contributions of presynaptic NMDA receptors. Biomolecules 5, 3448\u20133466 (2015).","journal-title":"Biomolecules"},{"key":"116_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/373151a0","volume":"373","author":"K Sakimura","year":"1995","unstructured":"Sakimura, K. et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor epsilon 1 subunit. Nature 373, 151\u2013155 (1995).","journal-title":"Nature"},{"key":"116_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/319774a0","volume":"319","author":"RG Morris","year":"1986","unstructured":"Morris, R. G., Anderson, E., Lynch, G. S. & Baudry, M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 319, 774\u2013776 (1986).","journal-title":"Nature"},{"key":"116_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1523\/JNEUROSCI.12-01-00021.1992","volume":"12","author":"S Davis","year":"1992","unstructured":"Davis, S., Butcher, S. P. & Morris, R. G. The NMDA receptor antagonist D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in vivo at intracerebral concentrations comparable to those that block LTP in vitro. J. Neurosci. 12, 21\u201334 (1992).","journal-title":"J. Neurosci."},{"key":"116_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt, D. C. & Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301\u20131308 (1991).","journal-title":"Am. J. Psychiatry"},{"key":"116_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1124\/jpet.103.052597","volume":"306","author":"FI Tarazi","year":"2003","unstructured":"Tarazi, F. I., Baldessarini, R. J., Kula, N. S. & Zhang, K. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306, 1145\u20131151 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"116_CR17","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.pharep.2016.05.009","volume":"68","author":"M Krzystanek","year":"2016","unstructured":"Krzystanek, M. et al. Extended neuroleptic administration modulates NMDA-R subunit immunoexpression in the rat neocortex and diencephalon. Pharmacol. Rep. 68, 990\u2013995 (2016).","journal-title":"Pharmacol. Rep."},{"key":"116_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.pharep.2015.01.017","volume":"67","author":"M Krzystanek","year":"2015","unstructured":"Krzystanek, M. et al. Effects of long-term treatment with the neuroleptics haloperidol, clozapine and olanzapine on immunoexpression of NMDA receptor subunits NR1, NR2A and NR2B in the rat hippocampus. Pharmacol. Rep. 67, 965\u2013969 (2015).","journal-title":"Pharmacol. Rep."},{"key":"116_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00213-011-2555-2","volume":"221","author":"KJ Davey","year":"2012","unstructured":"Davey, K. J. et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 221, 155\u2013169 (2012).","journal-title":"Psychopharmacology"},{"key":"116_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/S146114571300093X","volume":"17","author":"EM van der Zwaal","year":"2014","unstructured":"van der Zwaal, E. M., Janhunen, S. K., la Fleur, S. E. & Adan, R. A. Modelling olanzapine-induced weight gain in rats. Int. J. Neuropsychopharmacol. 17, 169\u2013186 (2014).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"116_CR21","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","volume":"25","author":"J Ferno","year":"2015","unstructured":"Ferno, J. et al. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain. Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 25, 923\u2013932 (2015).","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"116_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1017\/S1461145713000862","volume":"17","author":"S Skrede","year":"2014","unstructured":"Skrede, S. et al. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. Int. J. Neuropsychopharmacol. 17, 91\u2013104 (2014).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"116_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1124\/jpet.102.046987","volume":"305","author":"S Kapur","year":"2003","unstructured":"Kapur, S., VanderSpek, S. C., Brownlee, B. A. & Nobrega, J. N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305, 625\u2013631 (2003).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"116_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-015-0400-5","volume":"15","author":"JE Lambert","year":"2015","unstructured":"Lambert, J. E. et al. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. Bmc. Gastroenterol. 15, 169 (2015).","journal-title":"Bmc. Gastroenterol."},{"key":"116_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nature12480","volume":"500","author":"A Cotillard","year":"2013","unstructured":"Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585\u2013588 (2013).","journal-title":"Nature"},{"key":"116_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.83","volume":"3","author":"KJ Davey","year":"2013","unstructured":"Davey, K. J. et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl. Psychiatry 3, e309 (2013).","journal-title":"Transl. Psychiatry"},{"key":"116_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1073\/pnas.0605374104","volume":"104","author":"F Backhed","year":"2007","unstructured":"Backhed, F., Manchester, J. K., Semenkovich, C. F. & Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104, 979\u2013984 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"116_CR28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh, P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480\u2013484 (2009).","journal-title":"Nature"},{"key":"116_CR29","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.ebiom.2015.10.018","volume":"2","author":"SM Bahra","year":"2015","unstructured":"Bahra, S. M. et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine 2, 1725\u20131734 (2015).","journal-title":"EBioMedicine"},{"key":"116_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.135","volume":"5","author":"SM Bahr","year":"2015","unstructured":"Bahr, S. M. et al. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Transl. Psychiatry 5, e652 (2015).","journal-title":"Transl. Psychiatry"},{"key":"116_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1079\/PNS2001110","volume":"60","author":"SW Coppack","year":"2001","unstructured":"Coppack, S. W. Pro-inflammatory cytokines and adipose tissue. Proc. Nutr. Soc. 60, 349\u2013356 (2001).","journal-title":"Proc. Nutr. Soc."},{"key":"116_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1054\/npep.1999.0048","volume":"33","author":"W Langhans","year":"1999","unstructured":"Langhans, W. & Hrupka, B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 33, 415\u2013424 (1999).","journal-title":"Neuropeptides"},{"key":"116_CR33","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ejcn.2010.19","volume":"64","author":"Y Kadooka","year":"2010","unstructured":"Kadooka, Y. et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur. J. Clin. Nutr. 64, 636\u2013643 (2010).","journal-title":"Eur. J. Clin. Nutr."},{"key":"116_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3945\/jn.112.166132","volume":"143","author":"J Vulevic","year":"2013","unstructured":"Vulevic, J., Juric, A., Tzortzis, G. & Gibson, G. R. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J. Nutr. 143, 324\u2013331 (2013).","journal-title":"J. Nutr."},{"key":"116_CR35","doi-asserted-by":"publisher","first-page":"fiw233","DOI":"10.1093\/femsec\/fiw233","volume":"93","author":"R Grimaldi","year":"2017","unstructured":"Grimaldi, R. et al. In vitro fermentation of B-GOS: impact on faecal bacterial populations and metabolic activity in autistic and non-autistic children. Fems. Microbiol. Ecol. 93, fiw233 (2017).","journal-title":"Fems. Microbiol. Ecol."},{"key":"116_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1017\/S0007114516002269","volume":"116","author":"R Grimaldi","year":"2016","unstructured":"Grimaldi, R., Swann, J. R., Vulevic, J., Gibson, G. R. & Costabile, A. Fermentation properties and potential prebiotic activity of Bimuno(R) galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters. Br. J. Nutr. 116, 480\u2013486 (2016).","journal-title":"Br. J. Nutr."},{"key":"116_CR37","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1194\/jlr.R036012","volume":"54","author":"G den Besten","year":"2013","unstructured":"den Besten, G. et al. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J. Lipid Res. 54, 2325\u20132340 (2013).","journal-title":"J. Lipid Res."},{"key":"116_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12149-008-0216-2","volume":"23","author":"S Hirose","year":"2009","unstructured":"Hirose, S. et al. Role of NMDA receptor upon [14C]acetate uptake into intact rat brain. Ann. Nucl. Med. 23, 143\u2013147 (2009).","journal-title":"Ann. Nucl. Med."},{"key":"116_CR39","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.euroneuro.2017.11.001","volume":"28","author":"B Gronier","year":"2017","unstructured":"Gronier, B. et al. Increased cortical neuronal responses to NMDA and improved attentional set-shifting performance in rats following prebiotic (B-GOS\u00ae) ingestion. Eur. Neuropsychopharmacol. 28, 211\u2013224 (2017).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"116_CR40","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00213-016-4213-1","volume":"233","author":"S Singh","year":"2016","unstructured":"Singh, S. et al. Oral acetate supplementation attenuates N-methyl D-aspartate receptor hypofunction-induced behavioral phenotypes accompanied by restoration of acetyl-histone homeostasis. Psychopharmacology 233, 1257\u20131268 (2016).","journal-title":"Psychopharmacology"},{"key":"116_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4611","volume":"5","author":"G Frost","year":"2014","unstructured":"Frost, G. et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014).","journal-title":"Nat. Commun."},{"key":"116_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/srep37589","volume":"6","author":"Y Lu","year":"2016","unstructured":"Lu, Y. et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota. Sci. Rep. 6, 37589 (2016).","journal-title":"Sci. Rep."},{"key":"116_CR43","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.neuint.2013.10.006","volume":"63","author":"HM Savignac","year":"2013","unstructured":"Savignac, H. M. et al. Prebiotic feeding elevates central brain derived neurotrophic factor, N-methyl-D-aspartate receptor subunits and D-serine. Neurochem. Int. 63, 756\u2013764 (2013).","journal-title":"Neurochem. Int."},{"key":"116_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0306-4522(94)00586-T","volume":"66","author":"SL Eastwood","year":"1995","unstructured":"Eastwood, S. L., Burnet, P. W. & Harrison, P. J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 66, 309\u2013319 (1995).","journal-title":"Neuroscience"},{"key":"116_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"},{"key":"116_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.nut.2014.09.011","volume":"31","author":"FB Morel","year":"2015","unstructured":"Morel, F. B. et al. Preweaning modulation of intestinal microbiota by oligosaccharides or amoxicillin can contribute to programming of adult microbiota in rats. Nutrition 31, 515\u2013522 (2015).","journal-title":"Nutrition"},{"key":"116_CR47","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3945\/ajcn.2008.26242","volume":"88","author":"J Vulevic","year":"2008","unstructured":"Vulevic, J., Drakoularakou, A., Yaqoob, P., Tzortzis, G. & Gibson, G. R. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am. J. Clin. Nutr. 88, 1438\u20131446 (2008).","journal-title":"Am. J. Clin. Nutr."},{"key":"116_CR48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbi.2015.10.007","volume":"52","author":"HM Savignac","year":"2016","unstructured":"Savignac, H. M. et al. Prebiotic administration normalizes lipopolysaccharide (LPS)-induced anxiety and cortical 5-HT2A receptor and IL1-beta levels in male mice. Brain. Behav. Immun. 52, 120\u2013131 (2016).","journal-title":"Brain. Behav. Immun."},{"key":"116_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.schres.2008.05.011","volume":"103","author":"K Lykkegaard","year":"2008","unstructured":"Lykkegaard, K. et al. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. Schizophr. Res. 103, 94\u2013103 (2008).","journal-title":"Schizophr. Res."},{"key":"116_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1001\/jamapsychiatry.2017.1220","volume":"74","author":"JR Larsen","year":"2017","unstructured":"Larsen, J. R. et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 74, 719\u2013728 (2017).","journal-title":"JAMA Psychiatry"},{"key":"116_CR51","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.2337\/db16-0755","volume":"66","author":"RH Anderberg","year":"2017","unstructured":"Anderberg, R. H. et al. Glucagon-like peptide 1 and its analogs act in the dorsal Raphe and modulate central serotonin to reduce appetite and body weight. Diabetes 66, 1062\u20131073 (2017).","journal-title":"Diabetes"},{"key":"116_CR52","doi-asserted-by":"publisher","unstructured":"Hsu T. M., et al. A hippocampus to prefrontal cortex neural pathway inhibits food motivation through glucagon-like peptide-1 signaling. Mol. Psychiatry 2017, https:\/\/doi.org\/10.1038\/mp.2017.91..","DOI":"10.1038\/mp.2017.91"},{"key":"116_CR53","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1093\/schbul\/sbs076","volume":"38","author":"JT Coyle","year":"2012","unstructured":"Coyle, J. T. NMDA receptor and schizophrenia: a brief history. Schizophr. Bull. 38, 920\u2013926 (2012).","journal-title":"Schizophr. Bull."},{"key":"116_CR54","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1124\/mol.107.043786","volume":"73","author":"F Fumagalli","year":"2008","unstructured":"Fumagalli, F., Frasca, A., Racagni, G. & Riva, M. A. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol. Pharmacol. 73, 1484\u20131490 (2008).","journal-title":"Mol. Pharmacol."},{"key":"116_CR55","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/00004836-200603000-00015","volume":"40","author":"JM Wong","year":"2006","unstructured":"Wong, J. M., de Souza, R., Kendall, C. W., Emam, A. & Jenkins, D. J. Colonic health: fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40, 235\u2013243 (2006).","journal-title":"J. Clin. Gastroenterol."},{"key":"116_CR56","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1017\/S0007114512003066","volume":"109","author":"J Overduin","year":"2013","unstructured":"Overduin, J., Schoterman, M. H., Calame, W., Schonewille, A. J. & Ten Bruggencate, S. J. Dietary galacto-oligosaccharides and calcium: effects on energy intake, fat-pad weight and satiety-related, gastrointestinal hormones in rats. Br. J. Nutr. 109, 1338\u20131348 (2013).","journal-title":"Br. J. Nutr."},{"key":"116_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nature18309","volume":"534","author":"RJ Perry","year":"2016","unstructured":"Perry, R. J. et al. Acetate mediates a microbiome-brain-beta-cell axis to promote metabolic syndrome. Nature 534, 213\u2013217 (2016).","journal-title":"Nature"},{"key":"116_CR58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","volume":"34","author":"M Kluge","year":"2009","unstructured":"Kluge, M. et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrinology 34, 118\u2013128 (2009).","journal-title":"Psychoneuroendocrinology"},{"key":"116_CR59","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1039\/C6FO01467D","volume":"8","author":"SM Sarma","year":"2017","unstructured":"Sarma, S. M. et al. Kodo millet whole grain and bran supplementation prevents high-fat diet induced derangements in a lipid profile, inflammatory status and gut bacteria in mice. Food & Funct. 8, 1174\u20131183 (2017).","journal-title":"Food & Funct."},{"key":"116_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.biopsych.2016.12.031","volume":"82","author":"A Burokas","year":"2017","unstructured":"Burokas, A. et al. Targeting the microbiota-gut-brain axis: prebiotics have anxiolytic and antidepressant-like effects and reverse the impact of chronic stress in mice. Biol. Psychiatry 82, 472\u2013487 (2017).","journal-title":"Biol. Psychiatry"},{"key":"116_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","volume":"25","author":"P Dandona","year":"2004","unstructured":"Dandona, P., Aljada, A. & Bandyopadhyay, A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25, 4\u20137 (2004).","journal-title":"Trends Immunol."},{"key":"116_CR62","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1677\/joe.0.1770351","volume":"177","author":"JP Warne","year":"2003","unstructured":"Warne, J. P. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J. Endocrinol. 177, 351\u2013355 (2003).","journal-title":"J. Endocrinol."},{"key":"116_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115225","volume":"9","author":"AP Morgan","year":"2014","unstructured":"Morgan, A. P. et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS ONE 9, e115225 (2014).","journal-title":"PLoS ONE"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0116-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T16:07:36Z","timestamp":1693584456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0116-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,15]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["116"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0116-8","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,15]]},"assertion":[{"value":"22 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Clasado Biosciences Ltd, made a 10% financial contribution towards the study, as part of the BBSRC IPA scheme.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"66"}}